Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 14c

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of $0.47, $0.14 better than the analyst estimate of $0.33. Revenue for the quarter came in at $238.94 million versus the consensus estimate of $135.88 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Blackstone Mulls Pulling Plug on $3 Billion Stakes-for-Cash Deal - Bloomberg
• H&R Block (HRB) PT Raised to $60 at Barrington Research
• Crude Inventory Rose 17.2 Million Barrels Last Week - EIA